Franklin Resources
ALXN

Franklin Resources’s Alexion Pharmaceuticals ALXN Stock Holding History

Franklin Resources’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,902,026
Closed -$349M – 2526
2021
Q2 		$349M Buy
1,902,026
+11,357
+0.6% +$1.95M 0.13% 190
2021
Q1 		$289M Buy
1,890,669
+724,692
+62% +$112M 0.12% 210
2020
Q4 		$182M Buy
1,165,977
+538,775
+86% +$69.2M 0.08% 279
2020
Q3 		$71.8M Buy
627,202
+8,897
+1% +$960K 0.03% 470
2020
Q2 		$65.5M Buy
618,305
+927
+0.2% +$98.4K 0.03% 483
2020
Q1 		$55.4M Sell
617,378
-140,816
-19% -$13.8M 0.04% 441
2019
Q4 		$82M Sell
758,194
-407,545
-35% -$43.6M 0.04% 426
2019
Q3 		$114M Sell
1,165,739
-411,370
-26% -$46.4M 0.06% 333
2019
Q2 		$207M Sell
1,577,109
-47,852
-3% -$6.17M 0.11% 228
2019
Q1 		$220M Sell
1,624,961
-400,614
-20% -$49.8M 0.12% 218
2018
Q4 		$197M Buy
2,025,575
+41,416
+2% +$4.9M 0.12% 219
2018
Q3 		$276M Sell
1,984,159
-205,216
-9% -$25.7M 0.14% 196
2018
Q2 		$272M Sell
2,189,375
-30,400
-1% -$3.55M 0.14% 193
2018
Q1 		$247M Sell
2,219,775
-363,935
-14% -$43.5M 0.13% 201
2017
Q4 		$309M Buy
2,583,710
+243,650
+10% +$29.7M 0.15% 181
2017
Q3 		$328M Sell
2,340,060
-62,522
-3% -$8.49M 0.16% 173
2017
Q2 		$292M Buy
2,402,582
+439,714
+22% +$51.2M 0.15% 184
2017
Q1 		$238M Sell
1,962,868
-101,137
-5% -$13M 0.12% 199
2016
Q4 		$253M Buy
2,064,005
+1,358,305
+192% +$166M 0.13% 189
2016
Q3 		$86.5M Buy
705,700
+30,454
+5% +$3.92M 0.05% 382
2016
Q2 		$78.8M Buy
675,246
+105,602
+19% +$15M 0.04% 402
2016
Q1 		$79.3M Sell
569,644
-14,780
-3% -$2.17M 0.04% 402
2015
Q4 		$111M Buy
584,424
+5,869
+1% +$1.03M 0.06% 331
2015
Q3 		$90.5M Sell
578,555
-10,213
-2% -$1.86M 0.04% 378
2015
Q2 		$106M Buy
588,768
+5,236
+0.9% +$904K 0.05% 373
2015
Q1 		$101M Buy
583,532
+11,473
+2% +$2.08M 0.05% 388
2014
Q4 		$106M Sell
572,059
-114,344
-17% -$21.2M 0.05% 367
2014
Q3 		$114M Sell
686,403
-378,811
-36% -$62.2M 0.05% 339
2014
Q2 		$166M Sell
1,065,214
-102,976
-9% -$16.3M 0.07% 271
2014
Q1 		$178M Buy
1,168,190
+54,946
+5% +$8.74M 0.08% 253
2013
Q4 		$148M Buy
1,113,244
+111,424
+11% +$13.4M 0.07% 281
2013
Q3 		$116M Buy
1,001,820
+109,600
+12% +$12M 0.06% 311
2013
Q2 		$82.3M Buy
+892,220
New +$86M 0.05% 379

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Franklin Resources's ALXN Position: Q3 2021 in Review

Franklin Resources sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,902,026 shares — an estimated $349M sold.

Franklin Resources first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $349M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Franklin Resources reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Franklin Resources sold 1,902,026 Alexion Pharmaceuticals shares in Q3 2021, an estimated $349M.
  • Franklin Resources first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Franklin Resources's Alexion Pharmaceuticals position peaked at $349M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Franklin Resources's 13F filing for Q3 2021, filed 12 Nov 2021.